Epigentek

Executive Summary

Epigentek is a privately held US biotechnology company specializing in epigenetics research tools, including assay kits and reagents for studying DNA methylation and histone modifications. Founded in 2005 and based in Farmingdale, New York, the company serves academic, pharmaceutical, and biotechnology researchers. As a niche player in the growing epigenetics field, Epigentek benefits from increasing demand for epigenetic biomarkers in drug development and personalized medicine. However, the company remains small with no disclosed funding or valuation, and its private status limits visibility into financial performance. The lack of recent news or partnerships suggests a steady, low-profile business model. Nonetheless, Epigentek's established product catalog and long operating history provide a foundation for potential growth if it can capture a larger share of the epigenetics research market. The company's ability to expand through new product development or strategic collaborations could drive future value, but near-term catalysts are uncertain given its private nature.

Upcoming Catalysts (preview)

• Q3 2026Launch of Next-Generation Epigenetic Assay Kits50% success
• Q4 2026Strategic Partnership or Distribution Agreement with Major Life Science Supplier30% success
• Q1 2027Presentation of Novel Epigenetic Biomarker Services at Major Conference40% success